Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Restriction of non-opioid analgesics sold over-the-counter in Denmark: A national study of impact on poisonings

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Risk of Drug-Drug Interactions with Paracetamol in a Population of Hospitalized Geriatric Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • INDICES consortium
View graph of relations

Carboxylesterase 1 (CES1) metabolizes methylphenidate and other drugs. CES1 gene variation only partially explains pharmacokinetic (PK) variability. Biomarkers predicting the PKs of drugs metabolized by CES1 are needed. We identified lipids in plasma from 44 healthy subjects that correlated with CES1 activity as determined by PK parameters of methylphenidate including a ceramide (q value = 0.001) and a phosphatidylcholine (q value = 0.005). Carriers of the CES1 143E allele had decreased methylphenidate metabolism and altered concentration of this phosphatidylcholine (q value = 0.040) and several high polyunsaturated fatty acid lipids (PUFAs). The half-maximal inhibitory concentration (IC50 ) values of chenodeoxycholate and taurocholate were 13.55 and 19.51 μM, respectively, consistent with a physiological significance. In silico analysis suggested that bile acid inhibition of CES1 involved both binding to the active and superficial sites of the enzyme. We initiated identification of metabolites predicting PKs of drugs metabolized by CES1 and suggest lipids to regulate or be regulated by this enzyme.

Original languageEnglish
JournalCPT: pharmacometrics & systems pharmacology
Volume7
Issue number8
Pages (from-to)525-533
Number of pages9
ISSN2163-8306
DOIs
Publication statusPublished - Aug 2018

ID: 55270223